Anton Leicht on the BioMythos scenario where a Project Glasswing-style trusted access scheme creates wealth concentration in US pharma: "Let's say we have BioMythos, extremely good at all kinds of bio applications, both coming up with novel drugs and novel pathogens in the same way that Mythos is crazy good at cyber." "What does the US government do with that? It's not going to give it to the broader public. It's going to do another trusted access, like Project Glasswing style limited scheme.…